logo
Immunis Named Among Top 25 Biotech & Life Sciences Companies for 2025 by The Healthcare Technology Report

Immunis Named Among Top 25 Biotech & Life Sciences Companies for 2025 by The Healthcare Technology Report

Business Wire3 days ago
IRVINE, Calif.--(BUSINESS WIRE)-- Immunis, Inc., a clinical-stage biotech pioneering multi-active stem cell-derived biologics for age and disease-related immune dysregulation, was honored as one of the 'Top 25 Biotech & Life Sciences Companies for 2025' by The Healthcare Technology Report. This award is highly regarded by corporate executives, institutional investors, and industry leaders, cementing Immunis' reputation as a groundbreaking force in biomedical innovation.
Immunis received the accolade based on the ingenuity of its investigational stem cell-derived secretome therapy, IMM01-STEM, which aims to address age–related muscle atrophy, a disease that will affect 100% of humans.
Share
The Healthcare Technology Report (HTR) is a respected market research firm that reports on the developments, corporate actions, investment activity, and executive insights related to the healthcare industry. Awardees are chosen following an intensive evaluation of product innovation, leadership, strategic impact, and contributions to the global advancement of patient healthcare. Immunis received the accolade based on the ingenuity of its investigational stem cell-derived secretome therapy, IMM01-STEM, which aims to address age–related muscle atrophy, a disease that will affect 100% of humans. Not only does Immunis have the most clinically advanced secretome therapy in the world, but it is also tackling one of the most challenging health issues for which there is no pharmaceutical cure.
Impressively, Immunis is recognized alongside some of the industry's most influential biotech companies that are invoking actionable change in human healthcare. The coveted distinction inspires Immunis to continue revolutionizing patient-centered biotechnology and dismantling barriers towards its progress.
About Immunis Inc.
Immunis is a clinical-stage biotechnology company developing multi-active stem cell-derived biologics for the various manifestations of age-related diseases and immune dysregulation. The investigational product line leverages Immunis' leading-edge capabilities in stem cell secretome technology to deliver a product of all natural, all human immune modulators in their natural physiological concentrations.
For additional information about Immunis' programs, please visit our Pipeline.
Cautionary Note Regarding Forward-Looking Statements
This communication contains statements that constitute 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, as applicable. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations and assumptions, as well as other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only of the date as of which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. This communication is neither an offer to sell nor a solicitation of an offer to buy any of the securities described herein.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Finward Bancorp Announces Dividend
Finward Bancorp Announces Dividend

Business Wire

time2 days ago

  • Business Wire

Finward Bancorp Announces Dividend

MUNSTER, Ind.--(BUSINESS WIRE)--Finward Bancorp (Nasdaq: FNWD) (the 'Bancorp' or 'Finward'), the holding company for Peoples Bank (the 'Bank'), today announced that on August 15, 2025 the Board of Directors of Finward declared a dividend of $0.12 per share on Finward's common stock payable on September 12, 2025 to shareholders of record at the close of business on August 29, 2025. Bancorp Finward Bancorp is a locally managed and independent financial holding company headquartered in Munster, Indiana, whose activities are primarily limited to holding the stock of Peoples Bank. Peoples Bank provides a wide range of personal, business, electronic and wealth management financial services from its 26 locations in Lake and Porter Counties in Northwest Indiana and the Chicagoland area. Finward Bancorp's common stock is quoted on The NASDAQ Stock Market, LLC under the symbol FNWD. The website provides information on Peoples Bank's products and services, and Finward Bancorp's investor relations. Forward Looking Statements This Current Report on Form 8-K may contain forward-looking statements regarding the financial performance, business prospects, growth, and operating strategies of Finward. For these statements, Finward claims the protections of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Statements in this communication should be considered in conjunction with the other information available about Finward, including the information in the filings Finward makes with the Securities and Exchange Commission ('SEC'). Forward-looking statements provide current expectations or forecasts of future events and are not guarantees of future performance. The forward-looking statements are based on management's expectations and are subject to a number of risks and uncertainties. Forward-looking statements are typically identified by using words such as 'anticipate,' 'estimate,' 'project,' 'intend,' 'plan,' 'believe,' 'will' and similar expressions in connection with any discussion of future operating or financial performance. Although management believes that the expectations reflected in such forward-looking statements are reasonable, actual results may differ materially from those expressed or implied in such statements. Risks and uncertainties that could cause actual results to differ materially include: the Bank's ability to demonstrate compliance with the terms of the previously disclosed memorandum of understanding entered into between the Bank and the Federal Deposit Insurance Corporation ('FDIC') and Indiana Department of Financial Institutions ('DFI'), or to demonstrate compliance to the satisfaction of the FDIC and/or DFI within prescribed time frames; the Bank's agreement under the memorandum of understanding to refrain from paying cash dividends without prior regulatory approval; changes in asset quality and credit risk; the inability to sustain revenue and earnings growth; changes in interest rates and capital markets; inflation; customer acceptance of Finward's products and services; customer borrowing, repayment, investment, and deposit practices; customer disintermediation; the introduction, withdrawal, success, and timing of business initiatives; competitive conditions; the inability to realize cost savings or revenues or to implement integration plans and other consequences associated with mergers, acquisitions, and divestitures; economic conditions; and the impact, extent, and timing of technological changes, capital management activities, and other actions of the Federal Reserve Board and legislative and regulatory actions and reforms. Additional factors that could cause actual results to differ materially from those expressed in the forward-looking statements are discussed in Finward's reports (such as the Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K) filed with the SEC and available at the SEC's Internet website ( All subsequent written and oral forward-looking statements concerning Finward or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Except as required by law, Finward does not undertake any obligation to update any forward-looking statement to reflect circumstances or events that occur after the date the forward-looking statement is made. In addition to the above factors, we also caution that the actual amounts and timing of any future common stock dividends or share repurchases will be subject to various factors, including our capital position, financial performance, capital impacts of strategic initiatives, market conditions, and regulatory and accounting considerations, as well as any other factors that our Board of Directors deems relevant in making such a determination. Therefore, there can be no assurance that we will repurchase shares or pay any dividends to the holders of our common stock, or as to the amount of any such repurchases or dividends.

Klaviyo Announces Pricing of Secondary Offering of 6,500,000 Shares of Series A Common Stock by Certain Selling Stockholders
Klaviyo Announces Pricing of Secondary Offering of 6,500,000 Shares of Series A Common Stock by Certain Selling Stockholders

Business Wire

time2 days ago

  • Business Wire

Klaviyo Announces Pricing of Secondary Offering of 6,500,000 Shares of Series A Common Stock by Certain Selling Stockholders

BOSTON--(BUSINESS WIRE)--Klaviyo, Inc. (the 'Company') (NYSE: KVYO), the only CRM built for B2C brands, today announced the pricing of an underwritten public offering of 6,500,000 shares of its Series A common stock (the 'Offering') by certain of its existing stockholders (the 'Selling Stockholders'). In addition, such Selling Stockholders have granted the underwriter a 30-day option to purchase up to an additional 975,000 shares. The Company will not receive any proceeds from the sale of the shares being offered by the Selling Stockholders. The Offering is expected to close on August 21, 2025, subject to customary closing conditions. Barclays is acting as the underwriter for the offering. Barclays may offer the shares of Series A common stock from time to time in one or more transactions on the New York Stock Exchange, in the over-the-counter market, through negotiated transactions or otherwise at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices. A registration statement on Form S-3 relating to these securities was filed with the Securities and Exchange Commission (the 'SEC') on February 19, 2025 and became effective upon filing. The offering is being made only by means of a prospectus supplement and an accompanying prospectus. A copy of these documents may be obtained, when available, by visiting the SEC's website at or by contacting Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by phone 1-888-603-5847, or by email: barclaysprospectus@ This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any offer or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. About Klaviyo Klaviyo (NYSE: KVYO) is the only CRM built for B2C brands. Powered by its built-in data platform and AI insights, Klaviyo combines marketing automation, analytics, and customer service into one unified solution, making it easy for businesses to know their customers and grow faster. Klaviyo (CLAY-vee-oh) helps relationship-driven brands like Mattel, Glossier, CorePower Yoga, Daily Harvest and 176,000+ others deliver 1:1 experiences at scale, improve efficiency, and drive revenue. Forward-Looking Statements This press release includes certain 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, including among other things, statements concerning the completion of the offering. These forward-looking statements include, but are not limited to, plans, intentions, expectations, strategies and prospects and other statements contained in this press release that are not historical facts and statements identified by words such as 'will,' 'expects,' 'anticipates,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates' or words of similar meaning. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies or prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations, strategies and prospects will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control, including, without limitation, market risks and uncertainties and the satisfaction of customary closing conditions for an offering of securities, and other risks set forth under the caption 'Risk Factors' in the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, the preliminary prospectus supplement, the final prospectus supplement and the accompanying prospectus related to the offering and in subsequent filings made by the Company with the SEC. We assume no obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

Vornado JV Completes Sale of 512 West 22nd Street for $205 Million
Vornado JV Completes Sale of 512 West 22nd Street for $205 Million

Business Upturn

time3 days ago

  • Business Upturn

Vornado JV Completes Sale of 512 West 22nd Street for $205 Million

By GlobeNewswire Published on August 15, 2025, 03:02 IST NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) — Vornado Realty Trust (NYSE:VNO) announced today that its 55% owned joint venture has completed the previously announced sale of 512 West 22nd Street, a 173,000 square foot Class A office building, for $205 million. After repayment of the $123 million mortgage loan encumbering the property and transaction expenses, Vornado's share of the net proceeds is approximately $38 million. Vornado expects to recognize an approximate $11 million financial statement gain from this transaction in the third quarter. Vornado Realty Trust is a fully-integrated equity real estate investment trust. CONTACT Thomas J. Sanelli (212) 894-7000 Certain statements contained herein may constitute 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of performance. They represent our intentions, plans, expectations and beliefs and are subject to numerous assumptions, risks and uncertainties. Our future results, financial condition and business may differ materially from those expressed in these forward-looking statements. You can find many of these statements by looking for words such as 'approximates,' 'believes,' 'expects,' 'anticipates,' 'estimates,' 'intends,' 'plans,' 'would,' 'may' or other similar expressions in this press release. For a discussion of factors that could materially affect the outcome of our forward-looking statements and our future results and financial condition, see 'Risk Factors' in Part I, Item 1A, of our Annual Report on Form 10-K for the year ended December 31, 2024. Currently, some of the factors are interest rate fluctuations and the effects of inflation on our business, financial condition, results of operations, cash flows, operating performance and the effect that these factors have had and may continue to have on our tenants, the global, national, regional and local economies and financial markets and the real estate market in general. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store